Non-motor symptoms in PD- panel Q&A

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.” Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

There was a terrific question and answer session with panelists.  The panelists were:

• Peter LeWitt, M.D., Henry Ford Hospital
• Doree Ann V. Espiritu, M.D., Henry Ford Hospital, geriatric psychiatrist
• Edwin B. George, M.D., Ph.D., Wayne State University School of Medicine
• John L. Goudreau, D.O., Ph.D., Michigan State University, neuro-ophthalmologist
• Matthew Menza, M.D., Robert Wood Johnson Medical School
• Ronald F. Pfeiffer, M.D., University of Tennessee Health Science Center, neurologist

I’ve copied below notes that I took from the Q&A session with the panel.  (Time markings refer to the time in the recording, should you want to check out the original source yourself.)

Robin
—————————–

Question:  (43:57)  Relationship between impulsive behavior and PD?

Answer by Dr. Menza:  Impulse control disorders are major personality changes.  This happens largely due to medication.  Can happen with Sinemet but is more of a problem  with dopamine agonists.  Please talk to your physician about these problems as they are treatable.

Answer by Dr. LeWitt:  There is no profile for who is going to get these.  These behaviors can begin years after meds begin.

Question:  (46:38)  Are hallucinations caused from the disease or the meds?

Answer by Dr. Espiritu:  Some of the meds can cause hallucinations.  When dementia starts to develop, the risk for hallucinations increases.

Answer by Dr. George:  People with DLBD (diffuse Lewy body disease) can develop hallucinations without being on medications to trigger them.  We don’t have the answer how much pure PD in the absence of meds can trigger hallucinations.

Question:  (49:05)  Is losing sense of smell 20 years prior to diagnosis a coincidence or is this connected?

Answer by Dr. Pfeiffer:  Loss of sense of smell is a common and early finding in PD.  Many may not realize it.  This can happen much earlier than the onset of motor symptoms.  Twenty years is a long time but this could still be seen as being part of PD.

Question:  Any suggestions for erectile dysfunction when Viagra and similar meds don’t help?

Answer by Dr. Pfeiffer:  (50:27)  There are a variety of methods that can be used to treat ED, including injections, vacuum devices, rings, etc.  Urologists know about this.

Question:  What’s the impact of caffeine on PD?

Answer by Dr. LeWitt:  A study showed that neither PD tremors or essential tremors are worsened by caffeine.  (52:12)  Doesn’t seem to be any downside of caffeine.  Long term studies show that caffeine intake correlates with less progression of PD and lower incidence of PD.

Question:  What can we do about dizziness?

Answer by Dr. LeWitt:  Don’t accept the word “dizziness.”  Pin down what this means.  “Dizziness” is non-specific.  No medication can really help with this.  Is this:  low BP, inner ear problem, balance mechanism problems?

Question:  (54:19)  Is there a connection between nightmares and PD?

Answer by Dr. Menza:  Clinically, we worry that someone who develops bad nightmares may be in the early stages of developing hallucinations during the day.  So we want to know if there’s any problem during the day.  And, there are a number of sleep disorders that can include nightmares.

Question:  (55:37)  Is there any evidence that Seroquel is any more effective than Risperdal in treating hallucinations and behavioral problems in late stages of PD?

Answer by Dr. Menza:  Seroquel and Risperdal are antipsychotics.  Risperdal is a drug that I would not encourage those with PD to use.  Most of those with PD will not tolerate Risperdal.  It makes their PD worse.  There may be exceptions.  I don’t know if there’s any efficacy difference but there’s a tolerability difference.

Question:  (58:19)  Does DBS help with pain?

Answer by Dr. George:  Good question.  We don’t know.  There is some reason to think it would help.  But we usually wouldn’t use that sort of symptom as an indicator to go ahead and do this surgery.

Question (by Dr. Menza):  What do you think the relationship between pain syndromes and depression in PD is?

Answer by Dr. George:  (59:38)  Pain complaints are a major issue in those with depression.  They can certainly co-exist.

Question:  What’s your experience in using Ritalin to treat the symptoms of PD?

Answer by Dr. Espiritu:  (00:20)  Ritalin is a medication given for attention deficit disorders.  In geriatric patients, Ritalin (in the morning) can be used to augment an antidepressant (such as Zoloft, Paxil); it helps with fatigue and alertness.  There are no studies of Ritalin in PD.  Sometimes it is considered where there is extreme fatigue.  Another med that is used is Provigil.  A possible drawback can be anxiety, especially if the patient is already anxious.

Question:  (02:00)  Correlation between young-onset PD and seizures?

Answer by Dr. LeWitt:  Not aware of any connection.

Question (by Dr. LeWitt):  What is the connection between exercise and doing well with PD?  Is there evidence of this?

Answer by Dr. LeWitt:  There is lots of animal research (in animals with PD) that shows that exercise helps PD motor symptoms.  The evidence is convincing.

Answer by Dr. Pfeiffer:  In one study, the human equivalent would be a marathon a day for the amount of exercise the mouse got.  But there are human studies coming out of the Univ of Memphis that show that exercise helps.

Question:  Can loss of sense of smell be in both men and women?

Answer by Dr. Pfeiffer:  Yes, both men and women.

Question:  (04:15)  My wife is losing her teeth.  Her dentist told her it is due to the lack of saliva in the mouth from medication taken for PD.  Is this true?

Answer by Dr. Pfeiffer:  There is a literature on dental problems in PD, but it’s confusing.  Some reports say that people with PD have more dental problems due to the absence of saliva and the change in saliva pH.  On the other hand, there have been studies (one out of Japan in particular) showing that PD patients have better teeth.  It seems possible that absence of saliva could leave to poor dental care, gingivitis, and ultimately to loss of teeth, though this isn’t a common problem.

Answer by Dr. Goudreau:  (05:39)  The dentist could be referring to anticholinergic meds (such as Artane) which can dry up saliva quite remarkably.

Question:  (06:03)  Why is there an increase in muscle cramps in PD and what is recommended?

Answer by Dr. George:  Are we talking about dystonia or simple muscle cramps?  PD patients can get dystonic contractures which can occur as a result of medication (peak dose) and as a wearing-off effect of medication.  We typically see people with dystonia of the feet early in the morning from wearing-off of PD meds.  This can be confused with nocturnal leg cramps.  There could be a separate problem of neuropathy.  Have to sort out what sort of cramping the patient is experiencing.

Question:  Any contraindications for caffeine and Azilect?

Answer by Dr. LeWitt:  None known.  There are some foods to avoid with Azilect (rasagiline).  (07:51)

Question:  Treatment of compulsive behaviors.  If off agonists and behaviors persist, is the only choice to reduce Sinemet?

Answer by Dr. Espiritu:  The compulsive issues are very destructive in relationships.  After you’ve tried to decrease the meds that potentially cause these behaviors, and the behaviors persist, we need to take into consideration other meds, such as those for bipolar disorders.  For example, Depakote and lithium.  But these meds contribute to tremor and can worsen PD symptoms.  Antipsychotics are another choice to calm the behavior.  Have the patient see a therapist.

Question:  (10:15)  Is there a time late at night when you shouldn’t exercise?

Answer by Dr. Menza:  As best I understand, you can exercise any time you want.  It always helps with sleep.

Question:  Is sleepiness a biomarker for PD?

Answer by Dr. Menza:  As far as I know, no.

Question:  (11:05)  How do you treat the loss of libido in women?

Answer by Dr. Espiritu:  There was once talk about a nasal spray that was being tested in a small study in women.  There are many psychological issues that need to be addressed with regard to one’s libido.

Question:  (12:37)  Heavy-sweating in PD.

Answer by Dr. Pfeiffer:  40% of PDers have problems with increased sweating.  Usually face, neck, and maybe chest and arms.  Can be precipitated by activity (too much tremor or dyskinesia).  This can happen out of the blue.  Sometimes clothes have to be changed.  Presumably this occurs because of autonomic dysfunction.  This is bothersome but not dangerous.  Treatment is problematic.  I haven’t found an effective treatment for this — not botox, not propanolol.  If it’s due to dyskinesia or wearing-off, controlling PD symptoms should be addressed.

Question:  (15:30)  Impairment in visual-spatial processing.

Answer by Dr. Menza:  Complicated to sort out what in your environment you are going to pay attention to.  Maybe some of the AD drugs will help (maybe Namenda).  Obsessive-compulsive disorder is sometimes seen in PD.  It’s an anxiety disorder.  Treatment in PD is the same as treatment for OCD without PD.

Question:  (17:54)  Creatine, CoQ10, etc.

Answer by Dr. LeWitt:  No effectiveness seen in CoQ10.

Question:  (18:40)  How do you get involved in trials?

Answer by Dr. LeWitt:  See pdtrials.org (he said .com but it’s .org)

Question:  How can we slow PD?

Answer by Dr. LeWitt:  We don’t know.

Question:  What about gene therapy?

Answer by Dr. LeWitt:  There are several studies going on and some planned for in the US.

Question:  (20:40)  Can swollen ankles be caused by PD or PD meds?

Answer by Dr. George:  This can be a side effect from dopaminergic agents.  Also, there are changes in vascular tone that can occur in PD.  Other things can cause this such as heart failure.

Question:  What do you know about Azilect?  Can this halt progression of PD?

Answer by Dr. Pfeiffer:  There’s a clinical trial that’s been going on for several years now in Azilect.  News has been coming out about this trial.  The formal report has yet to be released.  Pre-clips have been released.  We don’t know which 2 of the 3 study objectives were met.  In August, the study results will be presented at a meeting in Spain.  At this point, the answer is “maybe.”

Question:  (23:40)  What is the danger of discontinuing Sinemet suddenly?

Answer by Dr. Goudreau:  One danger is NMS (neuroleptic malignancy syndrome).  Life-threatening syndrome.  This is rare.  Other danger is the risk associated with profound immobility that insues from stopping Sinemet:  increased risk of deep vein thrombosis, respiratory infections, etc.  “Drug holidays” have been discontinued because of these risks.  Sudden discontinuation of Sinemet is not recommended.

Question:  My “get up and go” has gotten up and went.  Can you address this?

Answer by Dr. Espiritu:  Apathy is common in PD.  Different from depression.  In apathy, there’s no drive to do anything.  Need to rule out depression.  Talk to a therapist about this.  Use of stimulants has not been studied.

Answer by Dr. LeWitt:  (26:33)  Medication trial in apathy is going on in a small way.  It’s not treated with anti-depressants.

Question:  Benefits of metronome therapy?

Answer by Dr. LeWitt:  This is undergoing research now.

Question:  (27:28)  What is being done to help with cognitive problems?

Answer by Dr. LeWitt:  There are some medication trials being studied for this.

Question:  Neupro patch.

Answer by Dr. LeWitt:  It will likely be returning to the market in the US next year.  Benefits of over-night effects.

Question:  How does someone decide to stop driving?

Answer by Dr. George:  There are many non-motor symptoms that affect driving.  Speak with your physician if you or your family has concerns about driving.  Often an occupational therapist can do a driving evaluation.

Question:  Music therapy.

Answer by Dr. LeWitt:  This is part of the symposium in September.  People with gait problems have been able to overcome these problems with music.

Question:  Balance and walking problems due to PD.

Answer by Dr. Pfeiffer:  Multi-factorial due to the case.  Does falling and hitting one’s head disrupt the inner ear?  Probably.  Balance problems occur later in PD.  If it occurs early in PD, you ares probably dealing with a Parkinson’s Plus syndrome.

Answer by Dr. George:  Antivert is a drug that suppresses the balance organ in the inner ear.  This drug can make your balance worse in PD.

Answer by Dr. Goudreau:  Important to determine if balance problems only occur when levodopa wears off.  Many things contribute to balance problems, such as a pinched disc, impaired vision due to cataracts, etc.  A physician needs to review this.  Balance is a common problem in PD but other reasons should be considered.

 

Visual Impairment in PD

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.” Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

One of the panelists, Dr. John Goudreau, gave a good, albeit short, presentation on the topic of “Visual Impairment in Parkinson’s Disease.”  He is a neuro-ophthalmologist at Michigan State University.

Copied below are the notes I took from his talk along with relevant Q&A.  (The time markers refer to the time in the recording, if you want to refer to the original.)

Robin

————————

Speaker:  John L. Goudreau, D.O., Ph.D., Michigan State University

Visual impairment is a common complaint in PD and ageing.  Many of the non-motor symptoms are common in ageing.

Symptoms:

  • decreased acuity
  • “tired eyes”
  • irritation (such as grittiness) or pain
  • blurred or double vision
  • visual-spatial confusion

Functional impact:

  • decreased reading
  • decreased driving
  • risk factor for dementia and visual hallucinations
  • contributing factor in falls

Causes of visual impairment in PD:

  • decreased blinking and dry eyes syndrome
  • quality of tears is poor
  • convergence insufficiency
  • loss of retinal dopamine (causing loss of color discrimination and loss of visual contrast sensitivity)
  • brain pathology of PD (causing visual-spatial impairment)

Subtle changes in vision are apparent in early PD.  Is this a biomarker for early PD?  (38:45)  We could introduce neuroprotective drugs earlier.

Changes in retinal function progresses in parallel with PD.  Is this a biomarker for disease progression?

Treatment of impaired vision:

  • hydration (aqueous drops 4-5 times/day, viscous or gel preparations, increase humidity in house, punctal occlusion for severe cases)
  • prisms
  • use of near vs. distance glasses
  • dopaminergic medications can help vision (and vision may fluctuate along with these meds)  (41:30)

Q&A with the Panel

Question:  Any link between PD and pal optic nerves (sp?)?

Answer by Dr. Goudreau:  The optic nerve fiber layer is not the one that seems to degenerate in PD.  The interconnection cells are degenerated in PD.

Question:  (56:40)  Severe double vision.

Answer by Dr. Goudreau:  With any of these non-motor symptoms, PD may not be the only explanation for them.  Severe double vision can be due to PD.  Need to see an ophthalmologist.  This can be treated with prisms.  Cover up one eye when reading.  Alternate the patch.

Question:  (14:36)  How do you do an eye exam in someone who has difficulty communicating?

Answer by Dr. Goudreau:  There are limits.  But there are some basic parts of the exam that could probably still be done.

Question:  (15:30)  Impairment in visual-spatial processing.

Answer by Dr. Goudreau:  Challenging area.

Emotional and Cognitive Aspects of PD

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.”  Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

The second speaker, Dr. Matthew Menza, gave a good presentation on the topic of “Emotional and Cognitive Aspects of Parkinson’s Disease.”

Even though this presentation was focused on PD, some references are made to LBD.  And, of course, there are emotional and cognitive aspects to all of the atypical parkinsonism disorders.

The most important thing I got from Dr. Menza’s presentation is that SSRIs should *not* be considered as the first line treatment in dealing with depression in PD.  A recent study showed that an old antidepressant, nortriptyline (Pamelor), performed better than Paxil, an SSRI.  Other drugs that are similar to nortriptylnie are Cymbalta and Effexor.

Of the atypical parkinsonism disorders, the only antidepressant that has been studied is Elavil (amitriptyline) in PSP.  Otherwise, I’m not aware of any studies.  You might take this recent PD research to your MD to find out if his/her recommendation would change based upon the new info.

Dr. Menza spent some amount of time on antipsychotics.  He explained that there was good data to recommend Clozaril and that in some studies Seroquel performed no better than the placebo.

He did talk about Lewy Body Dementia a couple of times, but I didn’t think his description was very good.  (Dr. Menza is a neurologist and psychiatrist.)

These are my notes from his presentation and his answers to the questions directed to him.  Of course it’s much better to watch the video yourself.

Robin


Robin’s notes from:

Emotional and Cognitive Aspects of Parkinson’s Disease
Matthew Menza, M.D., Prof. of Psychiatry and Neurology, Robert Wood Johnson Medical School

Non-motor symptoms of PD include:
* sleep disturbances, fatigue, and excessive daytime sleepiness
* depression
* drug reactions, including psychosis and impulsivity
* mild cognitive impairment to dementia

The non-motor symptoms have become the focus of research because they are so important to how patients feel day to day.

Depression:  about 40% have some.  It has a major impact on quality of life and functioning (faster progression of motor symptoms; greater decline in cognitive skills; greater decline in ability to care for self).  Depression often precedes the PD diagnosis.

Symptoms of depression include:  sadness, lack of appetite, sleep problems, lack of interest and motivation, fatigue, crying spells, etc.  Some of these symptoms are seen in PD without depression.  (6:22)

Depression is very inter-related with anxiety (worrying about things in an excessive way).  Anxiety is a common symptom in PD.

What causes depression in PD?  Probably a mix of neurochemical changes in the brain that accompany PD and the stress of living with an illness.

We encourage people to get involved in support groups.  There’s a lot of knowledge in SGs about handling day to day problems.  SG members may have common wisdom that MDs may not know about.

Try relaxation techniques to help yourself forget worries and get to sleep.  Even counting sheep.

Psycho-therapies are being modified and written expressively for those with PD.  Best to find a psychiatrist or psychologist who has experience with PD.

Exercise is a good treatment for depression.

NIH funded an 8-week trial of PD and paroxetine CR (an SSRI), nortriptyline (a tricyclic), and placebo.  This is the largest and first of placebo-controlled studies on antidepressants and PD.  This study is not yet published.  (Other studies are in the works.)  Big improvement in depression for both anti-depressants but nortriptyline was much better than paroxetine.  [paroxetine CR = Paxil CR; nortriptyline = Pamelor]  Nortriptyline affects both serotonin and norepinephrine in the brain.  Paroxetine affects only serotonin.  This study calls into question the use of SSRIs as first line treatment in PD.  Two other newer drugs that affect both serotonin and norepinephrine are Cymbalta and Effexor.  Paxil was effective for some in the study.  (23:48)

Sleep problems in PD are more common than would be expected from age alone.  50-75% of people with PD have trouble with sleep.  In their current study, sleep was the #1 predictor of quality of life (even more than motor problems).  The most common sleep problem is difficulty staying asleep (74-88% of patients).  Other problems:  poor quality sleep, difficulty falling asleep, muscle movements (PLMS and RLS; up to 15%), sleep apnea (up to 12%), RBD, morning headaches.

RBD (REM behavior disorder) is a particular concern.  PD accounts for 27% of RBD cases.  32% had injured themselves and 64% had assaulted their spouse.  Acting out dreams.  Can be a few vocalizations or something more dramatic.  People are reluctant to talk to MDs about this.  There’s a good treatment for RBD that works most of the time.

Excessive daytime sleepiness (EDS) occurs in up to 51% of PD patients.

Sleep attacks (sudden onset of sleep, usually without much warning) are associated with nearly every dopaminergic medication but especially Mirapex and Requip.  3.8% of PD patients had sudden attacks while driving.  Some still debate whether these attacks are caused by these drugs or EDS.

Sleep disturbances in PD may be related to nocturia (frequent need to urinate at night), pain, dystonia, akinesia, difficulty turning, etc.  Sleep is regulated by adrenergic, serotonergic, cholinergic, and various peptidergic symptoms which are disrupted (variably) in PD.  Depression is a major risk factor.  Dopaminergics can also worsen sleep (produce arousal and suppress REM).  (33:00)

Treatment of sleep disturbances includes:  exercise, sleep hygiene, intermittent use of sleep meds (Lunesta, Ambien, etc).  Some medications may help daytime sleepiness including Provigil, Ritalin (an older stimulant), and sometimes amantadine (Symmetrel).

Sleep hygiene:  regular sleep hours; avoid excess time in bed; regular get-up time regardless of sleep quality; avoid daytime naps (of 2 hours in length; 15 minutes is OK); use bed for sleep or sex; relaxation; physical activity; sunlight in morning; bedroom quality (noise, temperature, humidity); avoid evening stimulants; avoid large evening meals.  If you are worrying, get out of bed.  (36:34)

Two categories of unusual behaviors that sometimes accompany meds given for PD:  psychosis (hallucinations and delusions); impulse control disorders (including gambling, binge eating, buying, hypersexuality).

Psychosis is rare in untreated PD.  Can be caused by all PD meds though psychosis is somewhat more frequent with dopaminergic receptor agonists.  Biggest risk factor for developing psychosis is memory impairment.

Hallucinations (seeing something that isn’t really there) occurs in approximately 30% of PD patients.  Usually these are mild.  The problem is when hallucinations are frightening.

Delusions (belief that isn’t shared by other people in your world) occur in 3-17% of patients.  Can cause major problems and be very disruptive.  Generally later in illness when memory begins to fail.  Typically persecutory (eg, fear of being poisoned, infidelity).  Please bring these up with your MD.

There was just a large study on impulse control behaviors just discussed.  Seem to occur more frequently with Mirapex and Requip but can also occur with Sinemet.  (42:03)

In the face of these problems (psychosis or impulse control disorders), the first thing MDs do is reduce the dopamine medication.  “Motion-emotion conundrum.”  If reducing the parkinson meds doesn’t solve the problem, then MDs look to antipsychotics.  (43:08)  The first antipsychotic given is Seroquel.  If that doesn’t work, then Clozaril is tried.  Clozaril requires a weekly blood sample.  Clozaril is very effective.  (43:42)

In early PD, most develop a little of what could be described as “mild cognitive impairment.”  This is impairment of tasks requiring the frontal lobe of the brain — planning, judgment, and recall memory.  This doesn’t cause major problems.  Dopamine replacement leads to some improvement.  (44:39)

The more difficult thing is the more serious memory impairment that happens later in the disease.  Quite a few people develop this.  This is not Alzheimer’s.  This is much, much slower in development than Alzheimer’s, and generally less severe.  There are trials out there looking at the typical AD drugs (such as Exelon) in PD.  In one study, Exelon had a slightly positive response, and some with PD can take this drug.  It’s worth trying.  There is a question if Namenda will work.

Dealing with cognitive impairment includes:  household safety (and preventing wandering), reminders as to the structure of the house, day care, in-home help.

It’s important to educate yourself about psychiatric issues.  Sometimes you have to educate your physician about psychiatric issues in PD.  (46:39)

Question: Is bipolar a precursor to PD?
Answer:  I don’t think so but on the other hand certainly people with PD can develop bipolar disorder (though this would be unusual).  Bipolar disorder hits people early in life.  (48:00)

Question:  Can you elaborate on Lewy bodies?
Answer:  In Lewy body disease, there is wide distribution of Parkinson’s pathology across the brain.  This is a variant of PD where the cognitive impairment and memory impairment progresses much, much more rapidly than in normal PD.  And the individuals are much more sensitive to the adverse side effects of PD.  It’s a much more rapidly progressive illness than normal PD.  Not much is known about LBD.  It can be quite a trial.  (49:10)

Question:  What were the side effects related to nortriptyline?  (50:06)
Answer:  The newer antidepressants are better tolerated.  Surprisingly, nortriptyline (an older med) was well tolerated.  There was more constipation in the nortriptyline group.  Our lesson from the study:  don’t start with an SSRI.  (51:13)

Question:  When will a cure happen?
Answer:  Someday there will be a cure.  But what do you do now?  We need research on the problems we are having right now.  (51:56)

Question:  Can you comment on the French clozapine study?
Answer:  There have been two well-controlled Clozaril trials showing Clozaril is better than placebo for psychosis.  Weekly blood draws for six months can be a problem for some.  Some of the Seroquel trials did not show that Seroquel was any better than placebo.

Question:  Can we view panic reactions as a behavioral equivalent of a motor tremor?
Answer:  I suppose you could look at them that way.  Sometimes those with anxiety have panic attacks.  I don’t know if it’s the same neurochemically.

Question:  Depression vs. anger.  Can anger be a stimulus?
Answer:  Anger can motivate people to make changes in behavior.  If people are having a lot of anger, it’s usually based on relationships and chronic problems.  Counseling may be helpful in determining cause of anger.  Is the anger a personality change?

Question:  What determines sexual dysfunction?  Compared to what you used to do?  Frequency?
Answer:  These problems are happening in people who are older, some of whom have less interest in sex.  Autonomic dysfunction can contribute.  There are also relationship issues.  If something has dramatically changed compared to the past, then we look to some cause (medication?) for the problem.  (56:09)

Question:  If a person with PD is on bipolar meds, and needs an antidepressant, is there a conflict?  Are they more likely to become manic?  Any connection?
Answer:  This is complicated.  Lithium (a bipolar med) can sometimes not be at all well-tolerated in PD.  Med changes have to be made.  But there are some bipolar meds that those with PD can take.  Depression would be seen as a function of bipolar disorder.  In bipolar disorder, we generally try not to use antidepressants because this can worsen the mania.  But we do use them in conjunction with a mood stabilizer.  (58:10)

Question:  My husband becomes agitated and anxious.
Answer:  Agitation can be many things.  Impulsivity can be a personality change.  Is there a change in impulsivity?

Question:  How effective is Remeron for depression in PD?
Answer:  We have no idea.  Remeron is a new kind of antidepressant.  It works differently than Paxil, Prozac, that class.  Remeron tends to be very helpful with sleep.  It has a lot of antihistaminic and anticholinergic effects so it can make constipation worse.  Each antidepressant needs to be studied individually:  does this drug work in this person?

Question:  Is depression in PD hereditary?  (00:48)
Answer:  We don’t know.  We think that in non-PD depression has a hereditary component (“somewhat more likely” to develop PD).  Many people, however, with no family history develop depression, and many people with a family history of depression who never develop it.  Is there something different about PD and depression compared to PD without depression?  We don’t know but it’s a good question.

 

GI, Urological, Sexual and Other Functions – Dr. Pfeiffer’s talk

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.”  Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

The first speaker, Dr. Ron Pfeiffer, gave a wonderful presentation on the topic of “When Parkinson’s Interferes with Gastrointestinal, Urological, Sexual and Other Functions.”

Even though this presentation was focused on PD, lots of references are made to MSA.  And, of course, GI, urological, and other symptoms appear in all of the atypical parkinsonism disorders.

I’d heard Dr. Pfeiffer speak twice previously.  There was one new item from him:  To treat irritative urinary symptoms, he prefers the newer anticholinergics (Sanctura, Enablex, Vesicare — the first two are unlikely to cross the blood-brain barrier) compared to the older ones (Ditropan, Detrol, Levsin, Urispas, Pro-Banthine).  Tricyclics such as Tofranil can be used.

Also, he mentioned an important difference between MSA and PD:  “In PD, there can be sympathetic enervation to the heart is impaired.  (36:48)  In fact, it’s almost gone.  This doesn’t affect the functioning of the heart.  This may be useful in distinguishing PD from MSA because in MSA and in vascular parkinsonism the heart is normal.  (38:10)  This can be useful but it’s not sensitive enough.”

And I will relay his warning about Reglan:  “Don’t ever let an MD put you on Reglan, which works well but is terrible for those with PD.”  I think this caution would apply to those dealing with atypical parkinsonism disorder as well because the problem with Reglan is that it depletes dopamine.

These are my notes from his presentation and his answers to the questions directed to him.  Of course it’s much better to watch the video yourself.

Robin


Robin’s notes from:

When Parkinson’s Interferes with Gastrointestinal, Urological, Sexual and Other Functions  (he starts speaking at 1:48)
Ron Pfeiffer, M.D., Neurology, University of Tennessee Health Science Center

Non-motor features of PD:
* abnormalities of sensation
* behavioral changes
* sleep disturbances
* abnormalities of respiratory function
* autonomic dysfunction –> the focus of his presentation
* fatigue

The autonomic nervous system might be called the automatic nervous system.  It handles functions we don’t have to think about including:
* gastrointestinal –> he’ll spend most of his time here
* cardiovascular
* urological
* sexual
* thermoregulatory
* respiratory

In PD, things go wrong with the autonomic nervous system.

Gastrointestinal (starts at 5:00) dysfunction was described by James Parkinson.  GI symptoms include:
* salivary excess
* dysphagia
* nausea
* decreased frequency of bowel movements
* defecatory dysfunction
* weight loss

It had been thought that GI dysfunction was due to problems in the substantia nigra (midbrain).  Braak proposes that PD changes start in two other areas of the brain:  the olfactory center and the medulla (brain stem).  The medulla affects the vagus nerve, which controls a lot of the autonomic system.

Within the GI system, there’s another nervous system that controls the gut.  This is called the enteric nervous system.  Braak found alpha-synuclein deposition in the stomach.  So maybe PD originates not in the brain but in the stomach!  Maybe PD is transported from the stomach to the brain via the vagus nerve.  Dopamine deficiency can also be found in the enteric nervous system.

Weight loss in PD occurs in 52%.  (11:10)  May precede diagnosis.  Average weight loss is 7.2 lbs. (but 22% lose > 28 lbs!).  Reason is unclear:  reduced energy intake (but calorie intake is similar) or increased energy expenditure?

Excess saliva is experienced by 70-78% of PDers.  Saliva production is actually decreased.  Reasons saliva accumulates:  decreased swallowing frequency and efficiency, tendency for mouth to be open, stooped posture.

Treatment of excess saliva:
* anticholinergics: but these can make saliva more tenacious and viscous; systemic administration probably best avoided; sublingual atropine ophthalmic solution; can cause urinary retention and memory problems; [his slide says this but he didn’t discuss it:  glycopyrrolate avoids CNS but not peripheral AEs] * intraparotid botox: but there’s risk of pharyngeal muscle weakness
* antiparkinson medication: to improve swallowing efficiency
* gum and hard candy: very useful in a social situation
* tympanic neurectomy: he doesn’t recommend this (dubious benefit)

Dysphagia in PD occurs in 30-82%, according to questionnaires.  MBS (modified barium swallow) shows *some* abnormality in 75-97% though patients may be clinically asymptomatic.  In MBS, a barium-laced liquid, pudding, and cookie are swallowed.  MBS views mouth and throat, not esophagus.  Any phase of swallowing may be affected.

Complications of dysphagia:  (17:18)
* some degree of aspiration is present in 15-56% of those with PD.  Not necessarily full scale aspiration.  Aspiration = something getting past vocal cords.
* clinically silent aspiration present in 15-33%.  Coughing or choking when eating may be a clue.
* any abnormality increases risk of pneumonia.
[his slide says this but he didn’t discuss it:  * one particular abnormality (vallecular residue) present in 88% of patients without dysphagia.]

Oropharyngeal dysfunction diagnosed by:
* MBS
* pharyngeal manometry
* electromyography
* videomanofluroometry

Esophageal dysfunction diagnosed by:
* videofluoroscopy
* endoscopy
* esophageal manometry

Other problems that can affect the esophagus but may have nothing directly to do with PD:  (18:20)
* Zenker’s diverticulum: food collects; bad breath is common; people cough up undigested food hours after eaten; can be treated surgically
* cricopharyngeal bar: muscle that doesn’t relax when swallowing; can be treated surgically
* anterior osteophytes: arthritic changes
* achalasia: enteric nervous system is damaged and constricts down

At 19:32 there’s a good slide and discussion of how to approach diagnosis of dysphagia.

GERD can also affect swallowing.

Nausea in PD occurs in 16% of unmedicated people with PD.  (20:50)
Bloating occurs in 43% of unmedicated people
Gastroparesis (impaired emptying of stomach) may be responsible

Gastroparesis symptoms:  early satiety, sense of bloating, nausea/vomiting, weight loss

If there’s gastroparesis, alternate medication delivery routes can be sought:
* subcutaneous:  apomorphine, lisuride  (used in Europe)
* enteral (jejunal):  levodopa  (used in Europe)
* sublingual:  selegiline
* transdermal:  rotigotine  (only briefly available in US)

Prokinetic drugs can improve gastric emptying:  (23:00)
* dopamine antagonists:  domperidone works the best; this med is not available in the US; “your cagey neurologist” can probably get this medication for you from Canada.  Don’t ever let an MD put you on Reglan, which works well but is terrible for those with PD.
* serotonin 5-HT4 agonists:  Cisapride, Tegaserod, Mosapride, Prucalopride, Renzapride.  None of these is available in the US currently because of potential cardiac injury.

A gastric pacemaker can be placed to treat severe gastroparesis.  This has not been studied in those with PD.

The small intestine has not been studied in PD.  The clinical consequences of small intestine dysfunction are unclear.  Could this lead to abdominal bloating?  Could this lead to altered nutrient absorption, thereby causing weight loss?

Constipation = colonic inertia.  Decreased bowel movement frequency.  (25:12)
Defecatory dysfunction is more common than constipation, though he’s not sure everyone has found that.

The Honolulu Asian Aging Study showed that people who had less than one BM per day had:
* twice the likelihood of getting PD as compared to someone who had one BM per day, and
* four times as likely to get PD as compared to someone who had two or more BMs per day.
Unclear if this means that the presence of PD was evident years before the symptoms or if decreased bowel frequency has something to do with the etiology of PD.

Colon transit time is prolonged in PD.  Occurs in about 80% of PD patients.  (27:20)

The first step to treating constipation should always be to increase the amount of fiber and fluid one consumes.  (28:48)  Americans almost universally have a fiber-deficient diet.  If adding fiber to the diet doesn’t work, try a supplement.  Eight glasses of fluid a day need to be consumed.  Add a stool softener if that helps.  Next step is Miralax, available OTC.  Can be taken as needed or daily.  Next step is another choice of osmotic laxative.  If all else fails, enemas can be used.  It’s wise to avoid irritating laxatives for fear of damaging the enteric nervous system with prolonged used.

Medications have been looked at to speed up colon transit time:  Cisapride, NT3, Tegaserod, Prucalopride, and Lubiprostone (Amitiza).  Of these, only Amitiza is available.  The others have been withdrawn due to toxicity.  A teacher of his recommends pyridostigmine for this problem.  Surgical treatment is available:  colectomy (removal of part of the colon).

Defecatory dysfunction occurs in 66% of PD patients.  This includes increased straining, painful defecation, and incomplete emptying.  Some muscles are supposed to relax and others contract when having a BM.  In PD, this doesn’t always happen.  There can be insufficient intra-abdominal pressure.  Underlying mechanisms may be due to bradykinesia, rigidity, and dystonia of the sphincters (off-period phenomenon).  You can be tested for this but the tests (including defecography and anorectal manometry) are somewhat exotic.  There really isn’t any proven treatment for this problem.

In PD, there can be sympathetic enervation to the heart is impaired.  (36:48)  In fact, it’s almost gone.  This doesn’t affect the functioning of the heart.  This may be useful in distinguishing PD from MSA because in MSA and in vascular parkinsonism the heart is normal.  (38:10)  This can be useful but it’s not sensitive enough.

Orthostatic hypotension (drop in BP when standing) occurs in 58% of people with PD — in 20% it produces symptoms, while in 38% it produces no symptoms.  Antiparkinson meds can magnify this problem.  Lightheadedness (progressing to fainting) is the typical sensation but there are many others that people don’t realize.  (39:10)  Other symptoms include:  vision problems, impaired thinking, headache in a coathanger distribution, lower back or rear-end ache (because muscles deprived of blood), fatigue or lethargy.

Postprandial hypotension (BP drops after meals) can be triggered by carbohydrates (most likely culprit).  Sitting or standing may exacerbate.  Same symptoms as OH.  May develop within 15 minutes of eating, and may persist up to 3 hours.  In a normal person, eating a meal doesn’t cause BP to drop.  Deal with this by eating smaller meals more frequently.  Or rest/relax after eating until the problem passes.

Urinary dysfunction occurs in 27-39% of those with PD, according to newer studies.  (41:10)  Troublesome incontinence is in 15%.  Symptoms correlate with stage of disease.  Two types:  irritative (most common; consists of overactive bladder contraction) and obstructive.  Characteristics of irritative bladder are:  frequent urination, nighttime urination, urination of small amounts, urgency, and “urge” type incontinence.

To treat irritative symptoms, he prefers the newer anticholinergics (Sanctura, Enablex, Vesicare — the first two are unlikely to cross the blood-brain barrier) compared to the older ones (Ditropan, Detrol, Levsin, Urispas, Pro-Banthine).  Tricyclics such as Tofranil can be used.

Obstructive urinary symptoms include hesitancy and weak urinary stream.  May develop overflow incontinence.  Treatment is more difficult.  Intermittent catheterization is probably going to be the most effective treatment.  (44:05)

Bladder ultrasound can be a useful test to differentiate if this is an overactive or underactive bladder.

Question:  Will a colectomy have an impact on PD symptoms?  (45:45)
Answer:  I don’t think so.

Question:  Can drugs like Flomax be used in women with PD?
Answer:  I don’t think so.

Question:  Any relationship between ulcerative colitis and PD?
Answer:  I’m not aware of any.  Ulcerative colitis is an auto-immune disease.  PD is not an immune-related disease.

Question:  Is there any relationship between PD and sigmoid volvulus?
Answer:  It’s very rare and has to be treated surgically.

Question:  You mentioned injections in Europe to treat nausea and bloating. (48:22)
Answer:  Apomorphine infusions can be used to deliver meds if there’s gastroparesis but this med does not to treat gastroparesis itself.

Question:  What about diarrhea?  (51:12)
Answer:  Generally diarrhea isn’t a problem with PD per se.  Although if a person has severe constipation and gets impacted, eventually stool will liquify and go around the impaction area, and cause diarrhea.  Also, some meds can cause diarrhea.

Question:  My voice is raspy.  It feels tight around my throat.  What is this from?  (51:56)
Answer:  The most common speech problem in PD is a soft, breathy voice because people are not pushing enough air past the vocal cords or the vocal cords may not be closing tightly.  When you say “raspy,” this might be that the vocal cords are spasming.  Lee Silverman Speech Therapy has been developed for those with PD.

Question:  Should someone with PD who has frequent UTIs keep getting meds or does cranberry juice work?
Answer:  If you get an infection, you need antibiotics.  Cranberry juice may prevent UTIs.  If someone continues to get infections, a urologist may put him/her on chronic antibiotic therapy as a preventive measure.

Question:  What about sexual dysfunction?
Answer:  This is common but doesn’t get talked about much.  70% of so men have ED.  ED drugs can drop BP.  44% of men have decreased libido.  Much higher percentage of women have decreased libido.  Not much treatment for decreased libido.

Audience Member Comment:  PDers who drool give good wet kisses.

Question:  Is gall bladder inflammation related to PD?
Answer:  Nothing written about this.

Question:  Is there a portable electrical device to improve bowel function?
Answer:  I’m not aware of anything.

Question:  Bee stings caused my PD symptoms to dissipate.  Twice.  Can you speak to this?  France has been studying this.
Answer:  I’m not aware of anything in the literature about this.  Presumably this is affecting the body’s immune system.

Question:  How does Viagra affect PD or vice versa?
Answer:  Drugs like Viagra can be effective in treating ED but there can be a tendency for these drugs to cause the BP to drop.  It’s not cool to faint when you are trying to get other things done.  If you already have OH, you should probably stay away from these drugs.

 

Experimental AD drug that fights tau (not beta-amyloid)

There’s a lot of news coming out of Chicago during the big Alzheimer’s Disease conference there this week. The first part of this news article on an experimental drug fighting the protein tau is what caught my eye. Tau is the key protein involved in PSP and CBD. The article briefly mentions a second experimental tau-fighting drug that was used on those with mild cognitive impairment. The remainder of the article mentions Flurizan, where the development of this beta-amyloid-fighting drug has been halted, and the Elan/Wyeth experimental drug bapineuzumab. To my knowledge, beta-amyloid is NOT an issue in PSP or CBD. I read this article in the Miami Herald.

http://www.miamiherald.com/living/healt … 21968.html

Experimental Alzheimer’s drug shows early promise
Posted on Tue, Jul. 29, 2008
By MARILYNN MARCHIONE
AP Medical Writer

CHICAGO — For the first time, an experimental drug shows promise for halting the progression of Alzheimer’s disease by taking a new approach: breaking up the protein tangles that clog victims’ brains.

The encouraging results from the drug called Rember, reported Tuesday at a medical conference in Chicago, electrified a field battered by recent setbacks. The drug was developed by Singapore-based TauRx Therapeutics.

Even if bigger, more rigorous studies show it works, Rember is still several years away from being available, and experts warned against overexuberance. But they were excited.

“These are the first very positive results I’ve seen” for stopping mental decline, said Marcelle Morrison-Bogorad, director of Alzheimer’s research at the National Institute on Aging. “It’s just fantastic.”

The federal agency funded early research into the tangles, which are made of a protein called tau and develop inside nerve cells.

For decades, scientists have focused on a different protein – beta-amyloid, which forms sticky clumps outside of the cells – but have yet to get a workable treatment.

The drug is in the second of three stages of development, and scientists are paying special attention to potential treatments because of the enormity of the illness, which afflicts more than 26 million people worldwide and is mushrooming as the population ages.

The four Alzheimer’s drugs currently available just ease symptoms of the mind-robbing disease.

TauRx’s chief is Claude Wischik, a biologist at the University of Aberdeen in Scotland who long has done key research on tau tangles and studies suggesting that Rember can dissolve them.

He is an “esteemed biologist,” and the research “comes with his credibility attached to it,” said Dr. Sam Gandy of Mount Sinai School of Medicine in New York. He heads the scientific advisory panel of the Alzheimer’s Association.

In the study, 321 patients were given one of three doses of Rember or dummy capsules three times a day. The capsules containing the highest dose had a flaw in formulation that kept them from working, and the lowest dose was too weak to keep the disease from worsening, Wischik said.

However, the middle dose helped, as measured by a widely used score of mental performance.

“The people on placebo lost an average of 7 percent of their brain function over six months whereas those on treatment didn’t decline at all,” he said.

After about a year, the placebo group had continued to decline but those on the mid-level dose of Rember had not. At 19 months, the treated group still had not declined as Alzheimer’s patients have been known to do.

Two types of brain scans were available on about a third of participants, and they show the drug was active in brain areas most affected by tau tangles, Wischik said.

“This is suggestive data,” not proof, Wischik warned. The company is raising money now for another test of the drug to start next year.

The main chemical in Rember is available now in a different formulation in a prescription drug sometimes used since the 1930s for chronic bladder infections – methylene blue. However, it predates the federal Food and Drug Administration and was never fully studied for safety and effectiveness, and not in the form used in the Alzheimer’s study, Wischik and other doctors cautioned.

On Monday at the International Conference on Alzheimer’s Disease, other researchers reported encouraging results from a test of a different experimental drug that also targets tau tangles. That drug, by British Columbia-based Allon Therapeutics Inc., was tested in people with an Alzheimer’s precursor, mild cognitive impairment.

The tau-drug results are in stark contrast to the flop of Flurizan, which was aimed at blocking enzymes that form the beta-amyloid clumps. Myriad Genetics announced in June that it would abandon development of Flurizan after the failure. Full results were presented at the conference Tuesday.

Also, fuller results were given from a closely watched test of bapineuzumab, an experimental drug that aims to enlist the immune system to clear out the sticky brain clumps.

Its developers – New Jersey-based Wyeth and the Irish company Elan Corp. PLC – previously announced that the 240-patient study missed its main goal of improving patients’ mental performance at 18 months.

But the company found a silver lining – the drug appeared to help the roughly 60 percent of people in the study who did not have a gene that scientists think makes Alzheimer’s disease more severe.

The results back up the company’s claims of potential effectiveness in some patients, but now there are concerns about possible side effects. Twelve cases of a type of brain swelling occurred in those on bapineuzumab and none in the placebo group. The swelling caused few if any symptoms, company scientists said, but outside experts said it may have contributed to other side effects.

Those were two or more times more common in patients on bapineuzumab than people given the dummy drug. For example, cases of anxiety occurred in 11 percent versus 4 percent on placebo; paranoia, 7 versus 1 percent. Other complaints were vomiting, high blood pressure, weight loss, and back pain.

Three deaths occurred among the 124 patients given bapineuzumab, but they were not related to the drug, said Dr. Sid Gilman of the University of Michigan, who headed the study’s data safety monitoring board. One death was due to pneumonia and two others to worsening Alzheimer’s disease.

Investors reacted to the news by driving down Wyeth’s shares $5.01, or 11.1 percent, in after-hours trading.

Wyeth and Elan have already said they will move on to late-stage testing of bapineuzumab in more than 4,000 patients.